Detection of PAX8/PPARG and RET/PTC rearrangements is feasible in routine air-dried fine needle aspiration smears.

BACKGROUND The diagnostic limitations of fine needle aspiration (FNA), like the indeterminate category, can be partially overcome by molecular analysis. As PAX8/PPARG and RET/PTC rearrangements have been detected in follicular thyroid carcinomas (FTCs) and papillary thyroid carcinomas (PTCs), their detection in FNA smears could improve the FNA diagnosis. To date, these rearrangements have never been analyzed in routine air-dried FNA smears, but only in frozen tissue, formalin-fixed paraffin-embedded (FFPE) tissue, and in fresh FNA material. Fixed routine air-dried FNA samples have hitherto been judged as generally not suitable for testing these rearrangements in a clinical setting. Therefore, the objective of the present study was to investigate the feasibility of extracting RNA from routine air-dried FNA smears for the detection of these rearrangements with real-time polymerase chain reaction (RT-PCR). METHODS A new method for RNA extraction from routine air-dried FNA smears was established, which allowed analysis for the presence of four variants of PAX8/PPARG and RET/PTC 1 and RET/PTC 3, which were analyzed in 106 routine FNA smears and the corresponding surgically obtained FFPE tissues using real-time quantitative PCR (RT-qPCR). To assess RNA quality, an intron-spanning PAX8 cDNA was amplified. RESULTS Acceptable RNA quality was obtained from 95% of the FNA samples and 92% of the FFPE samples. PAX8/PPARG was detected in 4 of 96 FFPEs and in 6 of 96 FNAs. PAX8/PPARG was present in 4 of 10 FTCs and in 3 of 42 follicular adenomas (FAs). Similarly, RET/PTC was found in 3 of 96 FFPEs and in 4 of 96 FNAs. Two of 21 PTC samples and 3 of 42 FA samples carried this rearrangement. CONCLUSION These data are the first to show the feasibility of extracting RNA from routine air-dried FNA smears for the detection of PAX8/PPARG and RET/PTC rearrangements with RT-qPCR. These promising methodological advances, if confirmed in larger series of FNA and FFPE samples, may lead to the introduction of molecular analysis of routine air-dried FNA smears in everyday practice.

[1]  V. Marotta,et al.  The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. , 2012, The Journal of clinical endocrinology and metabolism.

[2]  H. Gharib,et al.  Thyroid nodule guidelines: agreement, disagreement and need for future research , 2011, Nature Reviews Endocrinology.

[3]  R. Paschke,et al.  Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. , 2011, The Journal of clinical endocrinology and metabolism.

[4]  B. Ljung,et al.  Molecular Testing for Somatic Mutations Improves the Accuracy of Thyroid Fine-needle Aspiration Biopsy , 2010, World Journal of Surgery.

[5]  Matthias M. Weber,et al.  Detection of Papillary Thyroid Carcinoma by Analysis of BRAF and RET/PTC1 Mutations in Fine-needle Aspiration Biopsies of Thyroid Nodules , 2010, World Journal of Surgery.

[6]  R. Paschke,et al.  Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns , 2010, Molecular and Cellular Endocrinology.

[7]  M. Brandi,et al.  Thyroid Cancer: Current Molecular Perspectives , 2010, Journal of oncology.

[8]  N. Eberhardt,et al.  Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis. , 2010, Clinical chemistry.

[9]  F. Pacini,et al.  Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. , 2010, The Journal of clinical endocrinology and metabolism.

[10]  Xuguang Zhu,et al.  Lessons from mouse models of thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[11]  Yuri E Nikiforov,et al.  Molecular diagnostics and predictors in thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[12]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[13]  M. Nikiforova,et al.  Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. , 2009, The Journal of clinical endocrinology and metabolism.

[14]  N. Eberhardt,et al.  The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid Cancer , 2008, PPAR research.

[15]  B. Zhu,et al.  Do Benign Thyroid Nodules Have Malignant Potential? An Evidence-Based Review , 2008, World Journal of Surgery.

[16]  M. Nikiforova,et al.  Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. , 2006, The Journal of clinical endocrinology and metabolism.

[17]  S. Asa,et al.  Pathogenetic mechanisms in thyroid follicular-cell neoplasia , 2006, Nature Reviews Cancer.

[18]  Gerard M Doherty,et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[19]  L. Hegedüs,et al.  The Thyroid Nodule , 2004 .

[20]  Y. Nikiforov,et al.  Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. , 2004, The Journal of clinical endocrinology and metabolism.

[21]  P. Kastner,et al.  Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.

[22]  T. Dwight,et al.  Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[23]  L. Sobrinho,et al.  Expression of PAX8-PPARγ1 Rearrangements in Both Follicular Thyroid Carcinomas and Adenomas , 2002 .

[24]  M. Nikiforova,et al.  PAX8-PPAR&ggr; Rearrangement in Thyroid Tumors: RT-PCR and Immunohistochemical Analyses , 2002, The American journal of surgical pathology.

[25]  G. Chiappetta,et al.  Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. , 2002, The American journal of pathology.

[26]  C. Cheung,et al.  Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[27]  V. Trovisco,et al.  PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma , 2006 .

[28]  L. Hegedüs,et al.  Clinical practice. The thyroid nodule. , 2004, The New England journal of medicine.

[29]  L. Sobrinho,et al.  Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. , 2002, The Journal of clinical endocrinology and metabolism.